Consolidated Investment Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Consolidated Investment Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,638	Closed	-$355K	–	46
2017 Q4	$355K	Sell	2,638 -14,412	-85%	-$2M	0.18%	46
2017 Q3	$2.49M	Hold	17,050	–	–	1.26%	30
2017 Q2	$2.65M	Hold	17,050	–	–	1.41%	28
2017 Q1	$2.48M	Hold	17,050	–	–	1.41%	28
2016 Q4	$1.86M	Hold	17,050	–	–	1.17%	33
2016 Q3	$2.07M	Hold	17,050	–	–	1.27%	33
2016 Q2	$2.41M	Hold	17,050	–	–	1.22%	34
2016 Q1	$2.23M	Hold	17,050	–	–	1.03%	40
2015 Q4	$2.4M	Buy	17,050 +1,940	+13%	+$269K	1.07%	37
2015 Q3	$2.01M	Buy	15,110 +3,062	+25%	+$527K	0.93%	43
2015 Q2	$2.12M	Hold	12,048	–	–	1%	38
2015 Q1	$2.08M	Buy	12,048 +7,433	+161%	+$1.28M	1%	39
2014 Q4	$756K	Buy	4,615 +277	+6%	+$46K	0.38%	58
2014 Q3	$697K	Buy	+4,338	New	+$667K	0.34%	55

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Consolidated Investment Group's JAZZ Position: Q1 2018 in Review

Consolidated Investment Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2018, closing a stake of 2,638 shares — an estimated $355K sold.

Consolidated Investment Group first reported a position in JAZZ in Q3 2014 and held it in 14 quarters. The position peaked at $2.65M in Q2 2017. 323 funds tracked by Wall St. Rank hold JAZZ as of Q1 2018.

Consolidated Investment Group reported no remaining Jazz Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Consolidated Investment Group sold 2,638 Jazz Pharmaceuticals shares in Q1 2018, an estimated $355K.
Consolidated Investment Group first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 14 quarters.
Consolidated Investment Group's Jazz Pharmaceuticals position peaked at $2.65M in Q2 2017.
323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2018.

Based on Consolidated Investment Group's 13F filing for Q1 2018, filed 20 Apr 2018.